Securities regulators say the role of Ipsen employee Dishant Gupta made him privy to details of the Epizyme acquisition. Gupta allegedly accumulated Epizyme shares while the deal was negotiated, then sold all of them hours after the transaction was announced.
The post SEC Charges Ipsen Worker for Insider Trading Tied to $247M Epizyme Acquisition appeared first on MedCity News.
